首页> 外国专利> PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR SARCOPENIA, CONTAINING IF1 AS ACTIVE INGREDIENT

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR SARCOPENIA, CONTAINING IF1 AS ACTIVE INGREDIENT

机译：用于预防或治疗肥胖症或嗜睡剂的药物组合物，含有IF1作为活性成分

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating obesity or sarcopenia, containing, as an active ingredient, IF1 having an effect of suppressed appetite or effects increased muscle mass and muscle production. According to the present invention, ATPase inhibitory factor 1 (IF1) exhibits, in an obesity-induced mouse model, effects of inhibited weight gain and decreased dietary intake without side effects, and exhibits, in obesity-induced or aged mouse, effects of increased muscle mass, increased muscle protein and muscle production, and thus is very useful as an agent for preventing, alleviating or treating metabolic diseases such as obesity, an agent for suppressing appetite and an agent for preventing, alleviating or treating muscle loss-related diseases such as sarcopenia.

机译：本发明涉及用于预防或治疗肥胖症或SARCOPENIA的组合物，含有ATP酶抑制因子1（IF1），更具体地，对药物组合物和用于预防或治疗肥胖或嗜睡剂，含有活性成分的食物， IF1具有抑制食欲或影响的影响，增加了肌肉质量和肌肉生产。根据本发明，在肥胖诱导的小鼠模型中，ATP酶抑制因子1（IF1）表现出抑制体重增加和饮食摄入量减少而没有副作用，并且表现出肥胖诱导或老年的小鼠，增加的影响肌肉肿块，增加肌肉蛋白质和肌肉产量，因此作为用于预防，减轻或治疗肥胖等代谢疾病的药剂非常有用，一种用于抑制食欲的药剂和用于预防，减轻或治疗肌损失相关疾病的药剂作为康迟腺。

著录项

公开/公告号US2022023393A1

专利类型
公开/公告日2022-01-27

原文格式PDF
申请/专利权人 KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION;CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION;
展开▼

申请/专利号US201917276212
发明设计人 MIN-JEONG SHIN;HYEON SOO KIM;JI HYUNG CHUNG;
展开▼

申请日2019-09-11
分类号A61K38/43;A61P3/04;A61P21;A61K38;
国家 US
入库时间 2022-08-24 23:33:57

相似文献

专利
外文文献
中文文献